BHVN Stock Summary and Trading Ideas (Biohaven Ltd. Common Shares | NYSE:BHVN)

Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder and others. Its pipeline products include: BHV-2000, BHV-7000, BHV-2100, BHV-8000, BHV-1310, BHV-1300, BHV-1400, BHV-1600, BHV-1530, and BHV-1500.

Biohaven Ltd. Common Shares trades on the NYSE stock market under the symbol BHVN.

As of September 11, 2026, BHVN stock price was flat at $12.79 with 45,748 million shares trading.

BHVN has a beta of 2.10, meaning it tends to be more sensitive to market movements. BHVN has a correlation of 0.07 to the broad based SPY ETF.

BHVN has a market cap of $1.93 billion. This is considered a Small Cap stock.

In the last 3 years, BHVN traded as high as $62.21 and as low as $7.48.

The top ETF exchange traded funds that BHVN belongs to (by Net Assets): XBI, VXF, VTWO, SCHA, PINK.

BHVN has underperformed the market in the last year with a price return of -8.7% while the SPY ETF gained +18.4%. However, in the short term, BHVN had mixed performance relative to the market. It has outperformed in the last 3 months, returning +15.5% vs +5.7% return in SPY. But in the last 2 weeks, BHVN shares have been beat by the market, returning -20.7% compared to an SPY return of -0.8%.

BHVN support price is $12.12 and resistance is $13.46 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BHVN shares will trade within this expected range on the day.